List of works - Jörg B. Engel

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

scientific article

Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.

scientific article published on 26 February 2013

Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.

scientific article published on 13 August 2014

Cervical endometriosis associated with malignant pleural mesothelioma mimicking cervical cancer--Occam's razor or the "third man".

scientific article published on 23 December 2010

Clomiphene-induced LH surges and cetrorelix

scientific article published in September 2002

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro

scientific article

Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.

scientific article

Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

scientific article published on 3 June 2011

Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.

scientific article published in March 2005

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone

scientific article

Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro ⬇️

scientific article published on April 1, 2012

Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.

scientific article published on 27 August 2009

Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238

scientific article published on 01 May 2005

Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.

scientific article published on July 2005

Immune escape of AKT overexpressing ovarian cancer cells ⬇️

scientific article published on March 4, 2013

Inhibin A/B in HMG or recombinant FSH ovarian stimulation with cetrorelix medication.

scientific article published in January 2001

Inhibin B on the day of HCG-administration is a predictive factor for failure in assisted reproduction cycles.

scientific article published on 19 December 2002

Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.

scientific article published on 5 July 2013

Myocardial infarction in the 34th week of gestation: case report ⬇️

scientific article published on October 25, 2011

Ovarian epithelial tumors and reproductive factors: a systematic review ⬇️

scientific article published on March 17, 2013

PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.

scientific article published on May 2012

Papillary squamotransitional cell carcinoma of the vagina

scientific article published on 15 September 2011

Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.

scientific article

Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.

scholarly article

Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages.

scientific article

Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study

scientific article published on 22 August 2006

Prognostic impact of infiltration of the vagina and/or uterus in women undergoing anterior pelvic exenteration for urothelial carcinoma of the bladder: results of a contemporary multicentre series.

scientific article published on 10 May 2014

Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.

scientific article

Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).

scientific article published on 9 October 2014

Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins

scientific article published on 01 December 2005

Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones

scientific article published on 18 August 2007

Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.

scientific article

The moral status of the embryo: an attempt at an analysis with the aid of David Hume’s ethics ⬇️

scientific article published on July 18, 2010

The role of regulatory T cells in ovarian cancer.

scientific article published on 16 February 2007

Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.

scholarly article

Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix ⬇️

scientific article published on June 1, 1998

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125

scientific article

Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.

scientific article published on January 2011

Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?

scientific article published in August 2002

Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening ⬇️

scientific article published on August 3, 2010

[Late interruption of pregnancy due to foetal disease: is an inductive method for the generation of ethical principles applicable?].

scientific article

[Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues]

scientific article published on 01 January 2006

List of works by Jörg B. Engel

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.

Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.

Cervical endometriosis associated with malignant pleural mesothelioma mimicking cervical cancer--Occam's razor or the "third man".

Clomiphene-induced LH surges and cetrorelix

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro

Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.

Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone

Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro ⬇️

Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.

Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238

Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.

Immune escape of AKT overexpressing ovarian cancer cells ⬇️

Inhibin A/B in HMG or recombinant FSH ovarian stimulation with cetrorelix medication.

Inhibin B on the day of HCG-administration is a predictive factor for failure in assisted reproduction cycles.

Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.

Myocardial infarction in the 34th week of gestation: case report ⬇️

Ovarian epithelial tumors and reproductive factors: a systematic review ⬇️

PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.

Papillary squamotransitional cell carcinoma of the vagina

Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.

Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.

Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages.

Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study

Prognostic impact of infiltration of the vagina and/or uterus in women undergoing anterior pelvic exenteration for urothelial carcinoma of the bladder: results of a contemporary multicentre series.

Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.

Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).

Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins

Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones

Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.

The moral status of the embryo: an attempt at an analysis with the aid of David Hume’s ethics ⬇️

The role of regulatory T cells in ovarian cancer.

Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.

Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix ⬇️

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125

Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.

Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?

Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening ⬇️

[Late interruption of pregnancy due to foetal disease: is an inductive method for the generation of ethical principles applicable?].

[Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues]